Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber assumes no liability for inaccuracies that may result from using this third-party tool, which is for website translation and not clinical interactions. You may request a live medical interpreter for a discussion about your care.
The Lymphoma Program is part of the Hematologic Oncology Treatment Center. Our specialists are experienced in providing treatment and care for the many varieties of lymphoid malignancies, including
chronic lymphocytic leukemia (CLL), B-cell neoplasms, and T-cell neoplasms. Your care will involve the best and most advanced treatments currently available, combined with new therapies based on research
in our laboratories and elsewhere in the field of lymphoma treatment.
Our program offers patients access to a multidisciplinary team of lymphoma experts with extensive experience caring for patients with lymphoid malignancies. This experience is particularly important because of the complexity of this type of cancer: There
are more than 20 tumor types, each with a unique natural history and each requiring a different approach to treatment.
We provide comprehensive services to patients with lymphoma, including:
New Patient Appointments
Yescarta is a CAR T-cell therapy that was approved by the FDA for aggressive, refractory non-Hodgkin lymphoma.
As a new Dana-Farber patient, find answers to questions about your first visit: what to bring, how to find us, where to park, and how to prepare.
We offer a wide range of services, from financial planning to creative arts to spiritual counsel, to support our patients through their cancer experiences.
The Blum Resource Center provides patients and family members with a
comfortable environment to learn more about disease treatment and
This video series and resource toolkit features Dana-Farber nutrition specialist Stacy Kennedy, MPH, RD, CSO, LDN, and explores how diet can help support your health and wellbeing during and after cancer treatment.